Clinical trials: Lymph Node Positive
Gastric Cancer
Efficacy and Safety of Tirelizumab Plus Chemotherapy Versus Chemotherapy Alone in Patients With Lymph Node Positive Gastric Cancer After Surgery
Lymph node positive patients after D2 radical surgery for gastric cancer, who started to be treated at Yixing people's Hospital in April 2021, were selected and enrolled into the study group according to the patients' wishes…
- Trial name
- NCT05844371
- Testing
- tirelizumab, chemotherapy with oxaliplatin + heroda
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Yixing People's Hospital
Breast Cancer
Axillary Radiotherapy or Axillary Lymph Node Dissection in Patients With Clinically Node- Positive Breast Cancer Undergoing Upfront Tailored Axillary Surgery
This trial is to investigate if in patients with clinically node positive breast cancer undergoing upfront surgery, treatment with TAS and ART is superior to ALND in terms of arm-related Quality of Life (QoL) and occurrence of…
- Trial name
- OPBC-10/ NOAX (NCT07140172)
- Testing
- Axillary lymph node dissection (ALND), Axillary radiotherapy (ART)
- Where
- 55 sites in United States, Austria and 9 more
- Volunteers
- 1,060 people
- Sponsor
- University Hospital, Basel, Switzerland
Melanoma
Nodal Radiation Therapy for Sentinel Lymph Node Positive Melanoma
This phase II trial seeks to determine the role of nodal radiation therapy after sentinel lymph node biopsy (SLNB) for patients with high risk sentinel lymph node positive melanoma who are planned for immunotherapy without…
- Trial name
- MelPORT (NCT04594187)
- Testing
- Immunotherapy, Quality-of-Life Assessment, Radiation Therapy
- Where
- 3 sites in United States
- Volunteers
- 168 people
- Sponsor
- M.D. Anderson Cancer Center
Esophageal Cancer
Adjuvant Chemotherapy With Paclitaxel and Cisplatin in Lymph Node-Positive Adjuvant Chemotherapy in the Treatment of the Lymph Node Positive Thoracic Esophageal Squamous Cell Carcinoma
Esophageal cancer is a highly aggressive malignancy with a poor overall outcome. Five year survival rate after radical esophagectomy is modest at about 40%.The patients with regional lymph node metastases have worse outcome than…
- Trial name
- NCT02461043
- Testing
- paclitaxel; cisplatin, radiation
- Where
- China
- Volunteers
- 386 people
- Sponsor
- Chinese Academy of Medical Sciences
Early Breast Cancer
Nab-paclitaxel in Combination With Pyrotinib in Postoperative Adjuvant Therapy for HER2-positive Breast Cancer
This is a multicenter, open-label, single-arm, prospective, phase II study. conducted to evaluate the efficacy, safety and tolerability of nab-paclitaxel plus pyrotinib in patients with lymph node-negative and tumor size ≤3 cm…
- Trial name
- NCT04659499
- Testing
- Nab-paclitaxel in combination with pyrotinib
- Volunteers
- 261 people
- Sponsor
- Peking Union Medical College Hospital
Cutaneous Melanoma
Minimal SN Tumor Burden
The purpose of this registry is to collect data in order to discover whether melanoma patients with minimal SN tumor burden should undergo a complete lymph node dissection (CLND) or not.
- Trial name
- Minitub (NCT01942603)
- Where
- 22 sites in Belgium, France and 8 more
- Volunteers
- 296 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Location and Biopsy of Axillary Lymph Nodes
Targeted Biopsy of Carbon Nanoparticles Labelled Axillary Node for CN+ Breast Cancer
To explore the feasibility of target biopsy of carbon nanoparticles labelled lymph node after neoadjuvant systemic therapy for cN+ breast cancer, and evaluate whether it can accurately predict axillary lymph node status after…
- Trial name
- NCT04482803
- Testing
- Carbon nanoparticles suspension injection will be injected into or around the cortex of the clinically assessed positive lymph nodes
- Where
- China
- Volunteers
- 159 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Mediastinal Lymph Node Enlargement, Sarcoidosis
Bronchoscopic Sampling Techniques in Sarcoidosis
The development of endobronchial ultrasound (EBUS) and EBUS-guided transbronchial needle aspiration (EBUS-TBNA) has improved the safety and diagnostic accuracy of the mediastinal lymph node (MLN) sampling.
- Conditions
- Mediastinal Lymph Node Enlargement, Sarcoidosis, Tuberculosis, Lymphomas
- Trial name
- NCT01836822
- Testing
- EBUS guided transbronchial forceps biopsy (EBUS-TBFB), EBUS guided transbronchial needle aspiration (EBUS-TBNA), large bore (19G) histologic needle biopsy of the mediastinal lymph nodes
- Where
- Poland
- Volunteers
- 90 people
- Sponsor
- Medical University of Warsaw
Breast Cancer
Efficacy and Safety Of Xeloda as Sequential Adjuvant Therapy After Chemotherapy in Breast Cancer
Select 600 cases of women with breast cancer of triple negative or Her-2 positive or with more than 4 axillary lymph node metastasis. All the patients were accepted the chemotherapy of Anthracycline and/or Taxane.
- Trial name
- NCT01662128
- Testing
- Xeloda
- Where
- China
- Volunteers
- 600 people
- Sponsor
- Tianjin Medical University
Breast Cancer
Positive Node Traced Before Neoadjuvant Chemotherapy (NAC)
To investigate this regression model by injecting and tracing carbon nanoparticles (CNs) into the fusion node prior to NAC in patients with breast cancer.
- Trial name
- NCT03355261
- Testing
- complete remission (CR) group, partial remission (PR) group, stable disease (SD) group
- Where
- 3 sites in China
- Volunteers
- 110 people
- Sponsor
- Shengjing Hospital
Tuberculosis
Role of EBUS-TBNA in Diagnosing TB in Mediastinal/Hilar Lymph Nodes
This is an observational prospective study. Role of EBUS-TBNA (endobronchial ultrasound transbronchial needle aspiration) is evaluated to diagnose tuberculosis in mediastinal and/or hilar lymph nodes.
- Trial name
- NCT01350674
- Testing
- EBUS-TBNA
- Where
- Belgium
- Volunteers
- 50 people
- Sponsor
- Centre Hospitalier Universitaire Saint Pierre
Breast Cancer Female, Breast Cancer
Omission of SLNB in Triple-negative and HER2-positive Breast Cancer Patients With rCR and pCR in the Breast After NAST
Currently, axillary surgery for breast cancer is considered as staging procedure that does not seem to influence breast cancer mortality, since the risk of developing metastasis depends mainly on the biological behaviour of the…
- Trial name
- NCT04101851
- Testing
- omission of SLNB
- Where
- 40 sites in Austria, Germany and 2 more
- Volunteers
- 350 people
- Sponsor
- Toralf Reimer, MD PhD
Breast Cancer
Letrozole in Preventing Cancer in Postmenopausal Women Who Have Received 4-6 Years of Hormone Therapy for Hormone Receptor-Positive, Lymph Node-Positive, Early-Stage Breast Cancer
RATIONALE: Estrogen can cause the growth of breast cancer cells. Letrozole may fight breast cancer by lowering the amount of estrogen the body makes.
- Trial name
- SOLE (NCT00553410)
- Testing
- Letrozole
- Where
- 164 sites in United States, Australia and 18 more
- Volunteers
- 4,884 people
- Sponsor
- ETOP IBCSG Partners Foundation
Squamous Cell Carcinomas
The Quarterback Trial: Reduced Dose Radiotherapy for HPV+ Oropharynx Cancer
This trial aims to directly compare a reduced radiation dose to the standard of care in HPVOPC for non-inferiority, thus allowing for direct comparison of outcomes between the two groups.
- Trial name
- NCT01706939
- Testing
- Reduced Dose Radiation, Standard Dose Radiation, Carboplatin
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Breast Cancer
Axillary Lymph Node Dissection Versus no Dissection in Breast Cancer With Positive Sentinel Lymph Node
The recently randomized trial (ASCOG Z0011) support that among patients with limited sentinel lymph node (SLN) metastatic breast cancer treated with breast conservation and systemic therapy, the use of sentinel lymph node biopsy…
- Trial name
- Z0011-China (NCT01796444)
- Testing
- Sentinel Lymph Node Biopsy, Intraoperative Pathological Examination, Axillary Lymph Node Dissection
- Where
- China
- Sponsor
- Shandong Cancer Hospital and Institute
Breast Cancer
Selective Avoidance of Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy In HER-2 Positive/Triple Negative Breast Cancer Patients With Excellent Radiologic Response to the Breast and Axilla, Prospective, Multi-center, Single-arm (ASLAN) Study
The aims of this study is to evaluate 5 year recurrence free survival when omit sentinel lymph node biopsy after neoadjuvant chemotherapy in triple negative or HER-2 positive breast cancer patients when physical examination…
- Trial name
- ASLAN (NCT04993625)
- Testing
- avoid axillary sentinel lymph node biopsy after neoadjuvant chemotherapy
- Where
- South Korea
- Volunteers
- 178 people
- Sponsor
- Jeong Eon Lee
Breast Adenocarcinoma
Neoadjuvant Toripalimab and Radiotherapy Treatment in N+ HR+ Breast Cancer
The goal of this clinical trial is to compare the efficacy and safety in patients with lymph node-positive HR+/HER2- breast cancer.
- Trial name
- NEOTRIO-HR (NCT06671262)
- Testing
- SBRT, Immuno-chemotherapy
- Where
- China
- Volunteers
- 74 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Breast Cancer
Dose-Dense Chemotherapy Plus Bevacizumab in High Risk Lymph Node Positive Breast Cancer: A Pilot Study
This research focuses on women with breast cancer whose disease has not significantly progressed, but who have 5 or more lymph nodes involved.
- Trial name
- NCT00378638
- Testing
- bevacizumab combined with dose dense chemotherapy
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Chap, Linnea I., M.D.
Cervical Cancer, Stage IB Cervical Cancer
Proton Beam Radiation Therapy and Cisplatin in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer and Positive Lymph Nodes
RATIONALE: Specialized radiation therapy, such as proton beam radiotherapy, that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue.
- Conditions
- Cervical Cancer, Stage IB Cervical Cancer, Stage IIA Cervical Cancer, Stage IIB Cervical Cancer
- Trial name
- NCT01019278
- Testing
- proton beam radiation therapy, radiation therapy treatment planning/simulation, cisplatin
- Sponsor
- Abramson Cancer Center at Penn Medicine
Node-positive Breast Cancer
Tailored Axillary Surgery With or Without Axillary Lymph Node Dissection Followed by Radiotherapy in Patients With Clinically Node-positive Breast Cancer (TAXIS)
RATIONALE: The use of tailored axillary dissection as a tailored procedure will avoid surgical overtreatment by selectively removing the lymph nodes that are affected by the cancer, thereby sparing many women the unnecessary…
- Trial name
- TAXIS (NCT03513614)
- Testing
- Tailored axillary surgery - both Arms, Radiotherapy - Arm A, Radiotherapy - Arm B
- Where
- 64 sites in United States, Argentina and 11 more
- Volunteers
- 1,500 people
- Sponsor
- University Hospital, Basel, Switzerland